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A functionalized benzimidazole, 1-(4-nitrobenzyl)-3-allyl-1H-benzo[d]imidazol-2(3H)-one, has been synthesized, and the crystal
structure was determined and analyzed. This compound crystallizes in the monoclinic, space group P2
1
/n (number 14) c with
cell parameters, 𝑎 = 7.12148(8) A˚, 𝑏 = 16.12035(17) A˚, 𝑐 = 13.04169(17) A˚, 𝛽 = 93.3043(11), 𝑉 = 1494.71(3) A˚3, and 𝐷calc =
1.375 g/mm3. The solid state geometry is stabilized by intermolecular 𝜋–𝜋 interactions along with the van der Waals interactions
which contribute to the stability of the crystal packing. Computational calculations have been used to properly understand the
main intermolecular interactions present in the crystal.
1. Introduction
Functionalized benzimidazoles represent an important class
of N-containing heterocyclic compounds and have received
considerable attention in recent times because of their appli-
cations as antiulcer, antihypertensive, antiviral, antifungal,
anticancer, and antihistamine activities among others [1–5].
They are important intermediates in many organic reactions
[6, 7] and act as ligands to transition metals for modelling
biological systems [8, 9]. In addition, the effectiveness of
benzimidazoles in the treatment of diseases such as ischemia-
reperfusion injury [10], hypertension [11], and obesity [12] has
been recently reported. Owing to their potential biological
activities and other possible applications of the benzimida-
zoles, a clear need exists for developing synthetic strategies
for the preparation of substituted benzimidazoles.
As a continuation of our research work devoted to the
development of substituted benzimidazol-2-one derivatives
[13–15], here we report on the synthesis of a new benzimid-
azol-2-one derivative displaying a new substitution pattern.
This compound has been obtained by the reaction of allyl-
bromide (4) with 1-(4-nitrobenzyl)-1H-benzo[d]imidazol-
2(3H)-one (3) in the presence of a catalytic quantity of tetra-
n-butylammonium bromide under mild conditions provid-
ing the disubstituted compound (5) (Scheme 1).
2. Materials and Methods
To 1H-benzo[d]imidazol-2(3H)-one (1) (0.30 g, 2.24mmol),
potassium carbonate (0.37 g, 2.68mmol) and tetra-n-
butylammonium bromide (0.07 g, 0.22mmol) in DMF
(20mL) were added to 4-nitro-benzylbromide (2) (0.58 g,
2.68mmol). Stirring was continued at room temperature
for 6 hours. The salt was removed by filtration and the
filtrate concentrated under reduced pressure. The obtained
compound (3) 1-(4-nitrobenzyl)-1H-benzo[d]imidazol-
2(3H)-one was separated by chromatography on a column
of silica gel with ethyl acetate/hexane (1 : 2) as eluent. The
compound was recrystallized from ethanol to give colorless
crystals (Scheme 2).
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Figure 1: ORTEP representation of 5 (displacement ellipsoids are drawn at the 50% probability level).
Figure 2: The unique molecule in the crystal structure of 5 (displacement ellipsoids are drawn at the 50% probability level).
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To the formerly obtained compound (3) (0.17 g, 0.63
mmol) allylbromide (4) (0.09 g, 0.76mmol) in DMF (10mL),
potassium carbonate (0.10 g, 0.76mmol) and tetra-n-buty-
lammonium bromide (0.02 g, 0.063mmol) were added
(Scheme 3). Stirring was continued at room temperature for
12 hours. The salt was removed by filtration, and the filtrate
concentrated under reduced pressure. The residue was sep-
arated by chromatography on a silica gel column with ethyl
acetate/hexane (1 : 1) as the eluent. The obtained compound
(5) was recrystallized from dichloromethane/hexane to give
colorless crystals of 5 (melting point = 95∘C, yield = 87%).
Single crystals of 5 were obtained from dichlorometh-
ane/hexane to give colorless crystals. A suitable crystal
was selected and measured on an Agilent SuperNova Atlas
Dual Source, Agilent Technologies, diffractometer using the
CrysAlisPro software.The crystal was kept at 200.00K during
data collection. Using Olex2 [16], the structure was solved
with the ShelXS [17] structure solution program using direct
methods and refined with the ShelXL [17] refinement pack-
age using least squares minimization. All hydrogen atoms
were fixed in geometrical positions. Nonhydrogen atoms
were refined with anisotropic displacement parameters. The
molecular connectivity and the crystal packing diagramwere
drawn using the Mercury (CCDC) program [18] and PyMol
[19]. Geometrical measurements were carried out using the
Mercury (CCDC) program [18].
Crystal Data for 5 C
17
H
15
N
3
O
3
(M = 309.32): mon-
oclinic, space group P2
1
/n (no. 14), a = 7.12148(8) A˚, b
= 16.12035(17) A˚, c = 13.04169(17) A˚, 𝛽 = 93.3043(11), V
= 1494.71(3) A˚3, Z = 4, T = 200.00(10) K, 𝜇(Cu K𝛼) =
0.795mm−1,𝐷calc = 1.375 g/mm
3, 14200 reflections measured
(8.74 ≤ 2Θ ≤ 146.06), 2935 unique (𝑅int = 0.0215) which were
used in all calculations.The final 𝑅
1
was 0.0353 (>2sigma(I)),
and wR
2
was 0.0962 (all data). CCDC number 948080. See
Figure 1 for the ORTEP representation of 5.
In order to obtain an additional insight into the inter-
molecular forces determining the crystal packing, compu-
tational calculations were used for the optimization of the
molecule and the calculation of the energies associated to
the different intermolecular interactions at the PM3 level of
calculation using the Spartan’08 software [20].
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Figure 3: Superimposed structures: optimized at PM3: red; X-ray:
green.
3. Results and Discussion
The details of the crystal data, data collection, and structure
refinements are shown in Table 1 and the unique molecule in
the crystal structure of 5 in Figure 2.
The title compound C
17
H
15
N
3
O
3
is a new heterocyclic
system deriving from 1H-benzo[d]imidazol-2(3H)-one. The
crystal structure of this molecule is formed by two fused
six- and five-membered rings linked to one benzyl and
one allyl groups. The fused-ring system is fundamentally
planar, with the maximum deviation from the mean plane
of 0.010 (6) A˚ for N3. The benzyl and allyl groups are almost
perpendicular to the benzimidazole plane but oriented in
opposite directions (Figure 2).
Table 1: Crystal data and structure refinement for 5.
Empirical formula C17H15N3O3
Formula weight 309.32
Temperature/K 200.00(10)
Crystal system Monoclinic
Space group P21/n
𝑎/A˚ 7.12148(8)
𝑏/A˚ 16.12035(17)
𝑐/A˚ 13.04169(17)
𝛼/∘ 90.00
𝛽/∘ 93.3043(11)
𝛾/∘ 90.00
Volume/A˚3 1494.71(3)
𝑍 4
𝐷calc/mg/mm
3 1.375
m/mm−1 0.795
𝐹(000) 648.0
Crystal size/mm3 0.225 × 0.1759 × 0.07
2Θ range for data collection 8.74 to 146.06
Index ranges −8 ≤ ℎ ≤ 8, −20 ≤ 𝑘 ≤ 19, −13
≤ 𝑙 ≤ 16
Reflections collected 14200
Independent reflections 2935[𝑅(int) = 0.0215]
Data/restraints/parameters 2935/0/216
Goodness-of-fit on 𝐹2 1.070
Final 𝑅 indexes [𝐼 ≥ 2𝜎 (𝐼)] 𝑅
1
= 0.0353, 𝑤𝑅
2
= 0.0930
Final 𝑅 indexes [all data] 𝑅
1
= 0.0394, 𝑤𝑅
2
= 0.0962
Largest diff. peak/hole/e A˚−3 0.18/−0.23
The theoretical PM3 calculations, after geometrical opti-
mization of the molecule, reveal torsion angles, and these
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Figure 4: Intermolecular 1H-benzo[d]imidazol-2(3H)-one–1H-benzo[d]imidazol-2(3H)-one 𝜋–𝜋 interactions.
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Figure 5: Arrays formed by intermolecular 1H-benzo[d]imidazol-
2(3H)-one–1H-benzo[d]imidazol-2(3H)-one 𝜋–𝜋 interactions.
3.733
Figure 6: Intermolecular 𝜋–𝜋 interactions.
have been compared with the experimental values. The
torsion angles of the 1H-benzo[d]imidazol-2(3H)-one sub-
stituents of the calculated geometry differ significantly from
the ones obtained in the solid state structure (Figure 2). The
C4–C7–N2–C8 angle changes from 106.83(12)∘ in the solid
state to 72.46∘ in the optimized geometry. A similar trend is
found for the C16–C15–N3–C8 that has a value of 111.84(13)∘
in the solid state and 72.56∘ in the optimized geometry.
The variations in the bond angle are not as important: N2–
C7–C4 that has a value of 111.52(10) in the solid state and
a
o
c
b
Figure 7:Molecular packing in the unit cell showing fourmolecules
in the asymmetric unit.
114.44∘ in the optimized geometry, N3–C15–C16 that has
a value of 112.65(10) in the solid state and 113.91∘ in the
optimized geometry. These results suggest that the change in
the conformation of themolecule will be stabilized by the for-
mation of intermolecular interactions in the crystal structure
overcoming the unfavorable conformational changes in the
substituents, Figure 3.
An analysis of the crystal packing shows the pres-
ence of intermolecular 𝜋–𝜋 interactions between the 1H-
benzo[d]imidazol-2(3H)-one rings. Two of those interac-
tions can be observed; in one of them, the two molecules
displaying an L shape are oriented in an antiparallel arrange-
ment, while in the second one, both molecules adopt a com-
plementary disposition one siting over the other, Figure 4. In
this second case, the benzene moiety of the benzoimidazole
ring of one molecule is pointing towards the nitrobenzene
fragment of the secondmolecule with anH-centroid distance
of 3.005 A˚; a new H–𝜋 interaction is formed stabilizing the
formation of such dimeric units.Thesemain interactions that
Journal of Chemistry 5
Figure 8: Observed arrays of parallel aromatic units involving
nitrobenzene–nitrobenzene interactions (bc plane) highlighted in
green and cyan.
Figure 9: Observed arrays (based on nitrobenzene–nitrobenzene
interactions) highlighted in green and cyan in the bc plane and in
the a direction inmagenta (formed by 1H-benzo[d]imidazol-2(3H)-
one–1H-benzo[d]imidazol-2(3H)-on 𝜋–𝜋 interactions).
Table 2: Bond lengths for 5.
Length (A˚)
C1–C2 1.3810(16)
C1–C6 1.3835(16)
C1–N1 1.4653(15)
C2–C3 1.3855(17)
C3–C4 1.3894(17)
C4–C5 1.3928(16)
C4–C7 1.5147(16)
C5–C6 1.3815(16)
C7–N2 1.4534(16)
C8–N2 1.3809(15)
C8–N3 1.3778(17)
C8–O3 1.2255(15)
C9–C10 1.3809(16)
C9–C14 1.3974(17)
C9–N2 1.3885(15)
C10–C11 1.3908(18)
C11–C12 1.3869(19)
C12–C13 1.3923(17)
C13–C14 1.3801(17)
C14–N3 1.3898(14)
C15–C16 1.4959(18)
C15–N3 1.4551(15)
C16–C17 1.306(2)
N1–O1 1.2241(15)
N1–O2 1.2182(15)
held together the molecules of 5 have 3.610 A˚ and 3.703 A˚
centroid-centroid distances; see Figures 4 and 5. These
directional interactions yield to the formation of ordered
arrays of parallel 1H-benzo[d]imidazol-2(3H)-one.
Intermolecular 𝜋–𝜋 interactions between the nitroben-
zene substituents are also found in the crystal structure,
having a 3.733 A˚ centroid-centroid distance, Figure 6. The
position of the molecules in the asymmetric unit is depicted
in Figure 7.
Thus, this arrangement generates parallel arrays of
nitrobenzene rings (bc plane) that are held together by
𝜋–𝜋 interactions (Figure 8), along with arrays of parallel
benzimidazole fragments in the adirection also based on𝜋–𝜋
interactions (Figure 9).
Computational studies at a semiempirical level of theory
PM3 (from X-ray geometries without optimization at PM3
level of theory) allow obtaining the relative stability of
the different 𝜋–𝜋 interactions observed in the solid state
structure (Figure 10). For this purpose, the relative energy
of the dimers displayed in Figure 10, each one containing
one of such intermolecular interactions, except the first one
containing two, was calculated with all the distances and
angles fixed according to the X-ray structure. Thus, cal-
culations predict that the 1H-benzo[d]imidazol-2(3H)-one-
1H-benzo[d]imidazol-2(3H)-one 𝜋–𝜋 interaction is more
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Figure 10: Calculated energy for the dimers observed at the X-ray crystal structure.
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Figure 11: Frontier orbitals. HF/3-21G∗ from X-ray geometry.
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Table 3: Bond angles for 5.
Angle (∘)
C2–C1–C6 122.80(11)
C2–C1–N1 118.25(10)
C6–C1–N1 118.92(10)
C1–C2–C3 118.24(11)
C2–C3–C4 120.66(11)
C3–C4–C5 119.33(10)
C3–C4–C7 120.98(11)
C5–C4–C7 119.67(11)
C6–C5–C4 121.07(11)
C5–C6–C1 117.88(10)
N2–C7–C4 111.52(10)
N3–C8–N2 106.21(10)
O3–C8–N2 126.65(12)
O3–C8–N3 127.14(12)
C10–C9–C14 121.51(11)
C10–C9–N2 131.52(11)
N2–C9–C14 106.97(10)
C9–C10–C11 117.10(11)
C12–C11–C10 121.32(11)
C11–C12–C13 121.63(12)
C14–C13–C12 116.94(11)
C13–C14–C9 121.49(11)
C13–C14–N3 131.63(11)
N3–C14–C9 106.88(10)
N3–C15–C16 112.65(10)
C17–C16–C15 124.92(15)
O1–N1–C1 118.32(10)
O2–N1–C1 118.49(11)
O2–N1–O1 123.18(11)
C8–N2–C7 123.76(10)
C8–N2–C9 109.93(10)
C9–N2–C7 126.31(10)
C8–N3–C14 110.02(10)
C8–N3–C15 123.80(10)
C14–N3–C15 126.18(10)
stable than the nitrobenzene–nitrobenzene 𝜋–𝜋 interaction.
The energy difference between the dimmers 1 and 3 is
2.49 kcal/mol, although it must be taken into consideration
that in the case of the first dimer, a second edge to face
interaction between the benzimidazole and the nitrobenzene
fragments is also present. The difference in calculated energy
between 2 and 3 is 1.93 kcal/mol.
The HOMO and LUMO − 2 are located on the 1H-
benzo[d]imidazol-2(3H)-one moiety and the LUMO and
HOMO + 2 on the nitrobenzene ring, and therefore, the
interaction between these frontier orbitals is the responsible
of the observed 𝜋–𝜋 interactions, Figure 11.
Tables 2, 3, and 4 summarize all bond lengths, bond
angles, and torsion angles obtained for the X-ray crystal
structure of 5.
Table 4: Torsion angles for 5.
Dihedral (∘)
C1–C2–C3–C4 1.02(18)
C2–C1–C6–C5 −0.42(17)
C2–C1–N1–O1 19.16(16)
C2–C1–N1–O2 −162.30(12)
C2–C3–C4–C5 −0.22(18)
C2–C3–C4–C7 −178.68(11)
C3–C4–C5–C6 −0.94(17)
C3–C4–C7–N2 108.96(13)
C4–C5–C6–C1 1.24(17)
C4–C7–N2–C8 106.83(12)
C4–C7–N2–C9 −73.63(14)
C5–C4–C7–N2 −69.49(14)
C6–C1–C2–C3 −0.70(18)
C6–C1–N1–O1 −159.22(12)
C6–C1–N1–O2 19.32(17)
C7–C4–C5–C6 177.54(11)
C9–C10–C11–C12 −0.59(17)
C9–C14–N3–C8 −0.49(12)
C9–C14–N3–C15 −179.71(10)
C10–C9–C14–C13 0.87(16)
C10–C9–C14–N3 −179.18(10)
C10–C9–N2–C7 −0.25(19)
C10–C9–N2–C8 179.34(11)
C10–C11–C12–C13 0.57(18)
C11–C12–C13–C14 0.17(17)
C12–C13–C14–C9 −0.87(16)
C12–C13–C14–N3 179.20(11)
C13–C14–N3–C8 179.44(11)
C13–C14–N3–C15 0.23(18)
C14–C9–C10–C11 −0.12(16)
C14–C9–N2–C7 −179.80(10)
C14–C9–N2–C8 −0.21(12)
C16–C15–N3–C8 111.84(13)
C16–C15–N3–C14 −69.05(15)
N1–C1–C2–C3 −179.02(10)
N1–C1–C6–C5 177.89(10)
N2–C8–N3–C14 0.37(12)
N2–C8–N3–C15 179.60(10)
N2–C9–C10–C11 −179.61(11)
N2–C9–C14–C13 −179.52(10)
N2–C9–C14–N3 0.42(11)
N3–C8–N2–C7 179.51(10)
N3–C8–N2–C9 −0.09(12)
N3–C15–C16–C17 127.76(15)
O3–C8–N2–C7 −0.37(19)
O3–C8–N2–C9 −179.98(11)
O3–C8–N3–C14 −179.75(11)
O3–C8–N3–C15 −0.51(19)
4. Conclusions
A new substituted benzo[d]imidazole-2(3H)-one has been
synthesized (1-(4-nitrobenzyl)-3-allyl-1H-benzo[d]imidazol-
2(3H)-one), and its crystal structure has been determined,
showing a solid state geometry stabilized by intermolec-
ular 𝜋–𝜋 interactions, benzimidazole–benzimidazole, and
nitrobenzene–nitrobenzene providing the formation of a sta-
ble three-dimensional network. Computational calculations
8 Journal of Chemistry
have allowed a better understanding of the nature of those
intermolecular interactions present in the crystal structure.
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